Figures & data
Figure 1. TNF-α expression in pg/mL. The upregulation in expression (p = 0.002) on stimulation with PMMA particles is significantly attenuated on pretreatment with cerivastatin at 150 μM (p = 0.005).
Figure 2. TNF-α expression in pg/mL. Monocytes pre-treated with cerivastatin at 150 uM and the Raf-MEK-ERK inhihitor UO-126 showed significant (p = 0.003) reductions in TNF-α expression.
Figure 3. MCP-1 expression in pg/mL. Monocytes exposed to PMMA showed increased expression relative to the control. Pretreatment with cerivastatin at 150 μM and the Raf-MEK-ERK inhihitor UO-126 suppressed PMMA-activated MCP-1 production (p < 0.05).
Figure 4. Western blot analysis illustrating the activity of the Raf-MEK-ERK intracellular pathway (ERK1 and 2) in response to PMMA particle challenge for 15 and 45 min (lanes 2 and 4). Similar challenges were repeated after 1 h of pretreatment with 150 μM cerivastatin (lanes 3 and 5). Monocytes were pretreated with UO-126 followed by PMMA challenge for 45 min (lane 6).
